Charles River Laboratories Raises FY23 Non-GAAP EPS Estimate To $10.30 – $10.90 From $9.90 – $10.90, Vs. Consensus Of $10.37
Portfolio Pulse from Benzinga Newsdesk
Charles River Laboratories has increased its FY23 Non-GAAP EPS estimate to $10.30 - $10.90 from $9.90 - $10.90, compared to the consensus of $10.37. The company also expects reported revenue growth of 2.5% - 4.5% for FY23.
August 09, 2023 | 11:29 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Charles River Laboratories has raised its FY23 Non-GAAP EPS estimate, which could positively impact its stock price. The company also expects a higher revenue growth for FY23.
Charles River Laboratories has raised its FY23 Non-GAAP EPS estimate, which is a positive signal for investors as it indicates the company's confidence in its future earnings. This could lead to an increase in the company's stock price. Additionally, the company's expectation of a higher revenue growth for FY23 could further boost investor confidence and positively impact the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100